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Background: The discovery of the fusion gene echinodermmicro tubule associated proteinlike 4-anaplastic lymphoma
kinase, EML4-ALK, in patients with non-small-cell lung cancer has led to the remarkable development of anaplastic
lymphoma kinase inhibitors, such as crizotinib. Consequently, the clinical outcomes of these patients have improved
dramatically. Herein, we report the case of a woman with ALK gene translocation-squamous cell lung cancer who
experienced a remarkable tumor response to crizotinib after two courses of failed chemotherapy.
Case presentation: A 55-year-old Chinese woman was diagnosed with cervical lymph node metastatic squamous
carcinoma. Chest computed tomography scan showed the primary tumor in the lower lobe of the right lung. The
patient had received two successive courses of first-line chemotherapy without tumor response. Tumor cells were
negative for wild-type of epidermal growth factor receptor/K-RAS variants; thus, she was not eligible for tyrosine kinase
inhibitor therapy. Unfortunately, increased levels of interleukin-6 and carcinoembryonic antigen, and computed
tomography scan results indicated cancer progression. Once crizotinib was approved by the China Food and Drug
Administration and the ALK gene translocation was identified in tumor cells by fluorescent in situ hybridization, the
patient commenced treatment with crizotinib. Remarkably, the tumor response to crizotinib was classified as partial
response after only 26 days of treatment commencement. The partial response status has been maintained to date
(23 weeks).
Conclusion: Considering this remarkable response to crizotinib, we can safely conclude that patients with squamous
cell lung cancer should have the option of undergoing ALK testing to determine if there is indication for crizotinib
treatment even after they have failed chemotherapy.
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Treatment of EML4-ALK fusion-positive non-small-cell
lung cancer (NSCLC) with the anaplastic lymphoma
kinase (ALK)-targeted agent, crizotinib, offers signifi-
cant improvement of clinical outcomes [1]. Herein, we
report the successful case of a patient with squamous
cell lung cancer and ALK gene translocation that expe-
rienced a remarkable response to crizotinib treatment
after two courses of failed chemotherapy.* Correspondence: dpbl_xhl@126.com
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A 55-year-old woman presented in May 2013 with cough,
sputum, and annihilation after activities of daily living, for
more than 20 days. She had no history of smoking or alco-
holism, but had undergone total hysterectomy because of
hysteromyoma in 2010. She was diagnosed with hyper-
tension three years earlier. On physical examination, an
enlarged right cervical lymph node was palpated. Chest
computed tomography (CT) scan (Figure 1A) indicated
the presence of a mass in the lower lobe of the right lung
and mediastinal lymph node enlargement. The patient
was then accepted and treated by the Department of Res-
piration for lung cancer stage IV with cervical lymph node
metastasis (T4N3M1).td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Chest computed tomography (CT) scans. Before the first chemotherapy treatment (May 2013) (A). After the second course of
chemotherapy (B). After 26 days (C) and 11 weeks (D) of crizotinib treatment.
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resected, and followed by biopsy and histologic examin-
ation. Hematoxylin and eosin (H & E) staining showed
the typical morphology of squamous cell carcinoma cells
(Figure 2A and B). Immunohistochemistry (IHC) ana-
lysis demonstrated that tumor cells were positive for
cytokeratin (CK) 5/6 (Figure 2C) and P63 (Figure 2D),
and negative for CK7, CK20, TTF-1, and Napsin A. The
positive rate of Ki-67 was 30%. Altogether, these results
confirmed the diagnosis of metastatic squamous cell car-
cinoma. The patient requested treatment with epidermal
growth factor receptor (EGFR)-tyrosine kinase inhibitors
(TKIs) because dozens of patients with squamous cell
carcinoma and EGFR mutations responded well to TKIs
at our institute. Amplification refractory mutation sys-
tem (ARMS) was used to assess EGFR and K-RAS gene
profiles to determine the presence of mutated variants.However, evidence of a normal genotype excluded the
patient from receiving EGFR-TKI treatment.
As first-line chemotherapy, the patient was initially
administered 135 mg/m2 (210 mg) of paclitaxel and
80 mg/m2 (120 mg) of nedaplatin. During treatment, the
patient’s condition did not seem to improve; thus, after a
20-day treatment, a second round of chemotherapy was
administered with 75 mg/m2 (120 mg) of docetaxel and
80 mg/m2 (120 mg) of nedaplatin. Unfortunately, increasing
levels of interleukin-6 (IL-6) (25.41 vs 16.03 pg/mL) and
carcinoembryonic antigen (CEA) (23.43 vs 7.13 ng/mL)
indicated cancer progression, which was confirmed by the
presence of multiple metastases in both lungs on CT scan
images (Figure 1B). Although not initially indicated, the
patient was then administered oral treatment with the
EGFR-TKI, erlotinib (1-month trial). However, this treat-
ment showed no efficacy.
Figure 2 Right cervical lymph node analysis. H & E staining (A and B). IHC staining of CK5/6 (C), P63 (D), and ALK (1A4) (E). ALK gene
translocation (FISH, arrows: split-apart signals for ALK gene translocation) (F).
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Food and Drug Administration (CFDA) in July 2013, the
patient underwent ALK testing. IHC staining (Clone 1A4,
Origene, 1:200) showed tumor cell positivity for ALK pro-
tein (Figure 2E). Then ALK break-apart fluorescent in situ
hybridization (FISH) was performed on 4-μm, formalin-
fixed, paraffin-embedded tissue sections. Slides were hy-
bridized with the LSI ALK Break Apart Rearrangement
Probe (Vysis, Abbott Molecular, Des Plaines, IL, USA),
and read on an epifluorescence microscope (BX41, Olym-
pus, Tokyo, Japan). The lung cancer cell line, NCI-H2228,
(American Type Culture Collection-ATCC) was used as
positive control. At least 50 tumor cell nuclei were ana-
lyzed and at least 15% of interpretable tumor cells harbo-
ring break-apart signals were used as the cutoff value [2].
As a result, the presence of ALK gene translocation was
confirmed (Figure 2F).
The patient underwent crizotinib treatment (250 mg/bid,
orally) for 26 days. After this period, symptoms, including
neck constriction and cough, were improved. Chest CTscan images demonstrated decrease in tumor size and
metastases. According to the Response Evaluation Criteria
in Solid Tumors (RECIST) guidelines (version 1.1), such
tumor response to crizotinib was classified as partial re-
sponse (PR) (Figure 1C). Follow-up chest CT scan per-
formed 11 weeks after the beginning of the treatment
revealed a dramatic reduction in tumor size and medias-
tinal lymph node, with nearly no presence of metastases in
both lungs (Figure 1D). IL-6 (3.34 vs 25.41 pg/mL) and
CEA (1.84 vs 23.43 ng/mL) levels were also reduced
23 weeks after the beginning of the therapy, which demon-
strated continuous partial response.
Discussion
According to the National Comprehensive Cancer Net-
work guidelines, ALK testing is not routinely performed
in patients with squamous cell lung cancer. Therefore,
this patient was not tested for ALK until crizotinib was
approved for marketing by the CFDA (June 23, 2013).
Unfortunately, neither chemotherapy nor EGFR-TKI
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ALK gene translocations have been previously detected
in patients with lung adenocarcinoma and light or non
smoking history [3,4]. To date, two studies have previously
reported cases of patients with mixed carcinoma and squa-
mous cell component harboring ALK rearrangements
[5,6], but these studies did not describe specific therapy or
diagnostic procedures. Another report showed that a pa-
tient with squamous cell lung cancer, harboring c-MET
amplification, had partially responded to crizotinib [7].
Herein, we report the case of a non-smoking woman with
squamous cell lung cancer and ALK gene rearrangement
who experienced remarkable response to crizotinib treat-
ment after failed chemotherapy. In concordance with other
studies on patients with lung adenocarcinoma treated with
crizotinib [8,9], this patient has remained in remission
(PR). Most importantly, such remarkable response was ob-
tained after two courses of failed chemotherapy.
Conclusion
Despite the low reconstruction rate of ALK gene, if appli-
cable, patients with squamous cell lung cancer should
have the option of undergoing ALK testing and receiving
crizotinib treatment. ALK testing and subsequent targeted
therapy could be an effective option for patients with non-
small cell lung cancer who present progression following
chemotherapy, radiotherapy, or any other treatment.
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